Do all patients with chronic phase CML require a diagnostic bone marrow biopsy in the modern TKI era?
Saved in:
| Main Authors: | Noel F. T. Fong, David M. Ross, David T. Yeung, Timothy P. Hughes, Naranie Shanmuganathan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-11-01
|
| Series: | Blood Neoplasia |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2950328025000731 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE
by: Ibrahim C. Haznedaroglu
Published: (2015-02-01) -
OPTIMIZATION OF TKI SELECTION IN CML: BALANCING EFFICACY, SAFETY, AND PATIENT PREFERENCES
by: Emel İşleyen Kaya
Published: (2024-12-01) -
THE HISTORY OF CHRONIC MYELOID LEUKEMIA (CML): FROM ARSENIC TO TYROSINE KINASE INHIBITORS (TKI)
by: Rüdiger Hehlmann
Published: (2025-07-01) -
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
by: Ibrahim C. Haznedaroglu
Published: (2013-12-01) -
Monitoring the response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML)
by: Ibrahim C. Haznedaroglu
Published: (2014-08-01)